Literature DB >> 11779672

Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients.

Naohito Shimoyama1, Megumi Shimoyama.   

Abstract

Three terminal cancer patients with severe dyspnea were treated with nebulized furosemide. The underlying causes of dyspnea varied. Twenty milligrams of furosemide was nebulized and inhaled four times each day. Dyspnea dramatically improved and could be controlled for weeks. No noticeable side effects were observed. Inhalation of nebulized furosemide seems to be an effective and useful treatment for dyspnea in terminal cancer patients, but these observations need to be confirmed in a randomized controlled trial.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11779672     DOI： 10.1016/s0885-3924(01)00367-0

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN： 0885-3924            Impact factor:   3.612


  9 in total

Review 1.  Dyspnea review for the palliative care professional: treatment goals and therapeutic options.

Authors:  Arif H Kamal; Jennifer M Maguire; Jane L Wheeler; David C Currow; Amy P Abernethy
Journal:  J Palliat Med       Date:  2012-01       Impact factor: 2.947

2.  The Effect of Aerosol Saline on Laboratory-Induced Dyspnea.

Authors:  C R O'Donnell; R W Lansing; R M Schwartzstein; Robert Banzett
Journal:  Lung       Date:  2016-12-21       Impact factor: 2.584

3.  Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.

Authors:  Robert W Hallowell; Richard Schwartzstein; Carl R O'Donnell; Andrew Sheridan; Robert B Banzett
Journal:  Lung       Date:  2019-11-15       Impact factor: 2.584

Review 4.  Causes and treatment of oedema in patients with heart failure.

Authors:  Andrew L Clark; John G F Cleland
Journal:  Nat Rev Cardiol       Date:  2013-01-15       Impact factor: 32.419

Review 5.  The symptomatic relief of dyspnea.

Authors:  Giovanni Elia; Jay Thomas
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

6.  An online survey of Australian physicians reported practice with the off-label use of nebulised frusemide.

Authors:  Phillip J Newton; Patricia M Davidson; Christine Sanderson
Journal:  BMC Palliat Care       Date:  2012-04-30       Impact factor: 3.234

7.  Combination adjunctive nebulized furosemide and salbutamol versus single agent therapy in COPD patients: A randomized controlled trial.

Authors:  Mohammadali Saba; Abdoulhossein Davoodabadi; Azin Ghaffari; Hamidreza Gilasi; Babak Haghpanah
Journal:  Ann Med Surg (Lond)       Date:  2020-07-18

8.  The efficacy of nebulized furosemide and salbutamol compared with salbutamol alone in reactive airway disease: a double blind randomized, clinical trial.

Authors:  Kambiz Masoumi; Arash Forouzan; Maryam Haddadzadeh Shoushtari; Samaneh Porozan; Maryam Feli; Mehdi Fallah Bagher Sheidaee; Ali Asgari Darian
Journal:  Emerg Med Int       Date:  2014-04-27       Impact factor: 1.112

Review 9.  Management of Breathlessness in Palliative Care: Inhalers and Dyspnea-A Literature Review.

Authors:  Helen Senderovich; Akash Yendamuri
Journal:  Rambam Maimonides Med J       Date:  2019-01-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.